Clinical Nurse Specialist Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Frances Burns

Clinical Nurse Specialist, Psychiatric/Mental Health, Adult Lanoka Harbor, NJ Clinical Nurse Specialist

NPI 1083688766 CMS profile 10782413

415 Route 9, Suite 2A, Lanoka Harbor, NJ 08734

Open in the dashboard

General payments

$9,511

413 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Frances Burns of Lanoka Harbor, NJ is reported in the CMS Open Payments database as having received $9,511 across 413 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 97th percentile of Clinical Nurse Specialist, Psychiatric/Mental Health, Adult profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $2,756 124
2024 General $3,010 112
2023 General $2,014 81
2022 General $812 48
2021 General $919 48

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Frances Burns
  • Clinical Nurse Specialist, Psychiatric/Mental Health, Adult median
  • Middle half of Clinical Nurse Specialist, Psychiatric/Mental Health, Adult
  • National median

In program year 2025, general payments to Frances Burns were reported at $2,756. Among 197 Clinical Nurse Specialist, Psychiatric/Mental Health, Adult profiles paid that year, the median was $174 and the middle half received between $71 and $653.

Show as a table
Year Frances Burns Clinical Nurse Specialist, Psychiatric/Mental Health, Adult median Middle half National median
2019 $0 — — $163
2020 $0 — — $114
2021 $919 $152 $38–$472 $132
2022 $812 $172 $73–$546 $149
2023 $2,014 $156 $56–$560 $160
2024 $3,010 $158 $39–$521 $164
2025 $2,756 $174 $71–$653 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. ITI, Inc. $1,730 61 payments
  2. AbbVie, Inc. $1,235 63 payments
  3. Janssen Pharmaceuticals, Inc $1,145 31 payments
  4. Otsuka America Pharmaceutical, Inc. $1,042 59 payments
  5. Axsome Therapeutics, Inc. $845 21 payments
  6. Lundbeck LLC $657 49 payments
  7. Alkermes, Inc. $462 9 payments
  8. Vanda Pharmaceuticals Inc. $429 16 payments
  9. Takeda Pharmaceuticals U.S.A., Inc. $287 21 payments
  10. Teva Pharmaceuticals USA, Inc. $265 12 payments
  11. Other $1,412 71 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $9,375 410 payments
  2. Education $135 3 payments
Products named General payments · program years 2021–2025
  1. CAPLYTA $1,405 49 payments
  2. REXULTI Psychiatry $939 52 payments
  3. VRAYLAR $928 41 payments
  4. Auvelity $845 21 payments
  5. REXULTI Psychiatry $631 47 payments
  6. INVEGA SUSTENNA $602 20 payments
  7. SPRAVATO $543 11 payments
  8. LYBALVI Cns $462 9 payments
  9. FANAPT $429 16 payments
  10. LYBALVI Cns $424 7 payments
  11. Other $4,117 194 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 22 drugs

Part D claims

631

Median for Nurse Practitioner: 389

Drug cost

$122,150

Median for Nurse Practitioner: $21,885

Branded share of claims

33.3%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Vraylar Cariprazine Hcl Brand 28 $37,647
Rexulti Brexpiprazole Brand 21 $36,143
Caplyta Lumateperone Tosylate Brand 14 $20,396
Oxtellar Xr Oxcarbazepine Brand 15 $12,886
Asenapine Maleate Generic 25 $7,312
Clozapine Generic 28 $1,250
Dextroamphetamine-Amphet Er Dextroamphetamine/Amphetamine Brand 14 $1,113
Dextroamphetamine-Amphetamine Dextroamphetamine/Amphetamine Brand 47 $942
Quetiapine Fumarate Generic 51 $870
Mirtazapine Generic 45 $746

The 10 drugs with the highest cost, of 22 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 5 billing codes

Paid by Medicare

$4,262

Medicare's payments for the services billed

Medicare patients

15

Average age 61

Services billed

56

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
Heart failure 0%
Atrial fibrillation 0%
Chronic kidney disease 0%
Cancer 0%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 25 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
CAPLYTA
$544 14 —
REXULTI
$506 21 —
VRAYLAR
$420 28 —
Auvelity
$273 — —
LYBALVI
$239 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 25 in the dashboard with a free account

Records

413 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Clinical Nurse Specialist, Psychiatric/Mental Health, Adult in New Jersey

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record